AMRX
Amneal Pharmaceuticals, Inc.
$17.01
-0.01 (-0.06%)
At close · Jul 10
Market Cap
$5.42B
Shares
319,022,792
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.01
Open$16.91
Day$16.69–17.16
52W$7.67–17.86
Avg vol 30d2.2M
Short int7.8M · 2.5% float · 2.9d
Short vol49%
Last earningsMay 7, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
Next earnings call
Aug 6, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Moderate
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+32%
above
Price vs 50-day avg
+17%
above
RSI (14)
69
neutral
MACD trend
Negative
52-week position
92%
near high
Momentum
relative strength
1-month return
+11%
trailing
6-month return
+29%
trailing
YTD return
+35%
this year
Relative strength
+20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $15 › 200d $13 — 50d above 200d
Institutional flow
Accumulating
8 of 315 funds reported for Jun 30 · net +89.3K sh shares · +1 new
Insider flow
Distributing
Net -$450.6K over 90 days · 100% sells
Short interest
Falling
2.46% of float · ▼ -1.1% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
315 holders — near 3-yr high, broad support
Squeeze score
55
elevated · 0–100
Fundamentals
EPS growth
+158%
Y/Y
Free cash flow
$269.9M
Valuation
P/E 45.9
rich
Balance sheet
$2.3B
net debt
Quant / Vol
risk profile
Volatility
33%
annualized · 1-yr
Max drawdown
−22%
past year
ATR
3.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
Net revenue
· 2026 Full Year
Initiated
$3.05B – $3.15B
prior FY $3.02B
midpoint +2.7% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+32%
Bullish
Price vs 50-day avg
+17%
Bullish
RSI (14)
69
Neutral
MACD trend
Negative
Bearish
52-week position
92%
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $15 › 200d $13 — 50d above 200d
Institutional flow
Accumulating
8 of 315 funds reported for Jun 30 · net +89.3K sh shares · +1 new
Insider flow
Distributing
Net -$450.6K over 90 days · 100% sells
Short interest
Falling
2.46% of float · ▼ -1.1% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
315 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $8
Now $17 · 92%
52-wk high $18
vs 200-day avg +32%
vs 50-day avg +17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted diluted EPS non-GAAP | $0.27 | first quarter of 2026 | — |
|
|
|||
| Adjusted EBITDA non-GAAP | $202M | first quarter of 2026 | — |
|
|
|||
| net debt leverage ratio non-GAAP | 3.7 | end of 2026 call | +5.7% |
|
|
|||
| retail generics products | 280 | current call | — |
| segment gross margin | 47.3% | Q1 call | — |
| Adjusted net income non-GAAP | $269M | Full Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AMRX
this stock
Amneal Pharmaceuticals, Inc.
|
$5.42B | +35.0% | +8.2% | 45.9 | 2.5% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$52.88B | +6.2% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$50.23B | +4.5% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.05B | -4.0% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AMRX | -0.8% | +11.0% | +29.0% | -1.7% | +35.0% |
| SPY | +0.8% | +2.0% | +8.9% | +0.7% | +10.2% |
| vs SPY | -1.6% | +9.0% | +20.1% | -2.4% | +24.8% |